Pfizer, BioNTech announce clinical studies for omicron-based vaccine
Pfizer and BioNTech said on Tuesday they have initiated clinical studies to evaluate an omicron-based vaccine for adults.
The trials will evaluate the "safety, tolerability, and immunogenicity" of the omicron-based vaccine for healthy adults between 18 and 55 years old, the companies said. About 1,400 participants will receive one of three combinations of the companies' current vaccine and the omicron-based vaccine.
"While current research and real-world data show that boosters continue to provide a high level of protection against severe disease and hospitalization with Omicron, we recognize the need to be prepared in the event this protection wanes over time and to potentially help address Omicron and new variants in the future,” said Kathrin U. Jansen, Ph.D., senior vice president and head of vaccine research & development at Pfizer, said in a statement.
The companies said 615 participants will receive a dose of the omicron booster after two doses of the current vaccine. Another 600 participants will receive a dose of the omicron booster after three doses of the current vaccine. The final 205 participants, who have not been vaccinated, will receive three doses of the omicron vaccine.
Pfizer and BioNTech said they expected to have initial findings in the first half of 2022. ABC News has also learned Moderna is expected to start similar human trials of an omicron-specific vaccine within the coming days.
-ABC News' Eric Strauss